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Abstract: In this article, we will discuss the main aspects to be considered to define standard operation
procedures (SOPs) for the creation of an induced pluripotent stem cell (iPSC) bank using cord blood
(CB)—or similar cell type—bank guidelines for clinical aims. To do this, we adapt the pre-existing
SOP for CB banking that can be complementary for iPSCs. Some aspects of iPSC manufacturing and
the particular nature of these cells call for special attention, such as the potential multiple applications
of the cells, proper explanation to the donor for consent of use, the genomic stability and the risk
of genetic privacy disclosure. Some aspects of the iPSC SOP are solidly established by CB banking
procedures, other procedures have good consensus in the scientific and medical community, while
others still need to be further debated and settled. Given the international sharing vocation of iPSC
banking, there is an urgent need by scientists, clinicians and regulators internationally to harmonize
standards and allow future sample interchange between many iPSC bank initiatives that are springing
up worldwide.
Keywords: SOP; cord blood bank; induced pluripotent stem cells; cell therapy; advanced therapies
medicinal products; HLA haplobank
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1. Introduction (From Cord Blood Banks into Induced Pluripotent Stem Cells Banks)
Umbilical cord blood (CB) has been used clinically since the late 1980s as a source of hematopoietic
stem cells to treat blood disorders such as lymphomas and leukaemia [1]. Given this long history of
clinical use, much can be learnt from CB banking for other more advanced cell therapies currently in
development. CB banks (CBBs) were initially established for hematopoietic progenitors transplants [2,3],
and large inventories of clinical-grade, HLA-typed CB units are stored all over the world. Having
large inventories of clinical-grade CB cells stored for transplantation leads to considering the use
of these units for alternative applications in cell therapy or in regenerative medicine that will also
help the sustainability of public CBBs [4]. One of the proposed uses is the production of induced
pluripotent stem cell (iPSC) lines from banked umbilical cord. In 2006, the seminal work of Yamanaka’s
group described the creation of iPSCs that are cells with embryonic stem-cell-like features made
from somatic adult cells [5]. Since then, the interest in stem cell research and therapies expanded
exponentially, as the ethical concerns of embryonic stem cells (hESCs) were not applicable and the
door to autologous treatment was opened [6]. Very soon after the discovery of iPSCs, it was argued
that the time and financial costs of personalized iPSC production would be unaffordable in most
cases and that the creation of an iPSC bank of homozygous HLA haplotypes could be an acceptable
allogeneic approach [7]. The concept of a bank of HLA matching homozygous donors had already
been proposed for embryonic stem cells before [8,9]. With just a few homozygous donors with wide
HLA immunological compatibility among the population, a wide percentage of the population would
be provided with the possibility of iPSC-derived therapies [10]. Consequently, the idea of repurposing
CB banks for creating HLA-homozygous iPSC banks developed [11]. Cells from cord blood are good
candidates as starting material for iPSCs because they are genetically young, CBB count on thousands
of cryostored CB units are already HLA-typed, and protocols for reprogramming them into iPSCs
are well established [12,13]. Rao and colleagues reviewed the success and opportunities arising from
coupling CBBs to iPSC banks and how one could benefit the other [14]. Several CBBs have already set
themselves to the task of creating an iPSC bank from the stored homozygous CB units. The Catholic
University of South Korea described the generation of 13 clinical-grade HLA-homozygous iPSC lines
made from several HLA-typed banked tissues, including cord blood [15] and more specifically, the
Korean CHA Medical Centre described their experience repurposing the CB bank for haplobanking
of HLA-homozygous iPSCs and the generation of 10 lines that would match 41.07% of the Korean
population [16]. For other populations with higher diversity of HLA types, the number of haplotype
cell lines required increases, though the benefits are still significant with a feasible number of iPSC cell
lines. A study on the UK population estimated that 10 selected homozygous donors would provide
a complete match on HLA-A, HLA-B and HLA-DR for 37.7% of the population, and a beneficial
match (just one HLA-A or one HLA-B mismatch) for 67.4% [9], and for the highly ethnically diverse
population of California, it was estimated that fewer than 80 haplolines would cover the needs of more
than 50% of the population [17]. HLA-homozygous iPSC initiatives are starting in other countries
such as Spain (IPS-PANIA project), led by the Banc de Sang y Teixits (BST) and CMRB, in Australia
(Murdoch Children’s Research Institute) and in the UK (CGT Catapult initiative) that use peripheral
blood. For that matter, the Global alliance for iPSC therapies (GAiT) was formed with the mission: “an
international initiative to support the implementation and clinical application of therapies derived from
induced pluripotent stem cells” and provides guidance and support for the creation and harmonization
of iPSC banks globally.
Creating a clinical-grade, Good Manufacturing Practice (GMP)-standard human iPSC bank with
cell samples that are intended to be used by numerous users for both research and clinical applications
is a complex process that has to be carefully thought about and well documented, with a quality
management structure in place. This can cause work plans, applications, ethics and costs to differ
greatly between iPSCs for research use or for clinical applications. When considering the ethics
of iPSC applications, it overcame the dilemma of embryo destruction posed by hESC; however,
other ethical issues still arise such as the risk of undesired differentiation of cells and malignant
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transformation, misuse for unauthorised reproductive cloning or animal–human chimera creation [18].
The International Stem Cell Banking Initiative (ISCBI) published an extensive article on the development
of iPSC banks (or seed stocks) for clinical applications [19]. Specific policies, manuals, forms, registries
and standard operating procedures (SOPs) have to be created. Figure 1 shows a schematic description
of the process of creating an iPSC bank from CB banks’ samples and identifies the areas for which the
different SOPs have to be created.
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Many of the SOPs already existing for CBBs can be adapted to an iPSC bank (termed iPSCB).
In order to elp standardize policies and SOPs for CBBs, the Foundation for the Accreditation of
Cellular Therapy and NETCORD published a d cument with guidelin s for cor bl o collection and
banking describing the main considerations for the bank structure and operations and providing a list
of relevant SOPs [20]. These documents can be useful for updating and revising CBB SOPs and offer a
reference point in many aspects for creating a new SOP for iPSC banks (Table 1).
Table 1. Possible adaptation of required Policies and SOPs from the NetCord-FACT International
Standards for CB collection, banking and release for administration [20].
Subject
Standard
CBB iPSC Bank
Donor recruitment B3.1 1, C3.3.1
Informed consent B3.1.3, C3.1.3
Donor eligibility criteria and determination B3.1.5, C3.4.6
Interaction between the CB collection site and the CBB Interaction between CBBs and the iPSC bank B3.1.6
Infant donor health B3.1.7, C3.1.6, C3.1.7
Storage of CB units, associated samples, maternal samples and documentation
at the CB collection site
Storage of iPSC aliquots, associated samples
and documentation associated to original CB
units
B3.1.10, C6.7
Transport and shipping of the CB unit, associated samples, maternal samples
and documentation to the CB processing facility
Transport and shipping of the CB unit,
associated samples and documentation to the
iPSC production centre
B3.1.41, C3.1.13
Labelling of the CB unit, associated samples, reference samples, retention
samples, maternal samples and associated documents at the CB collection site
and CB processing facility
Labelling of the iPSC aliquots, associated
samples, reference samples, retention samples
and associated documents at the original CBB
and iPSC production centre
B3.1.14, C3.1.10, C6.5, D2.1.4
CB unit acceptance criteria for receipt, processing, cryopreservation and storage B3.1.15, B3.1.19, D2.1.1, D2.1.7,
Process control, including product specifications and nonconforming products B3.1.16, B3.1.21, C3.1.11, D2.1.3, D2.1.8
Storage of reference samples, retention samples and maternal samples for
testing
Storage of reference samples and retention
samples for testing B3.1.17, D4.1.12, D4.1.2
Communicable disease testing, microbial cultures, hemoglobinopathy testing and other testing. B3.1.18, B3.1.19, D2.1.7
Notification of mothers or their responsible physicians and/or governmental agencies, when required, of positive or indeterminate
communicable disease and/or genetic test results B3.1.20
Listing, search, selection, reservation, release and distribution of CB units Listing, search, selection, reservation, releaseand distribution of iPSC aliquots B3.1.23
HLA typing B3.1.25, D2.1.9, E3.2.1
Data management B3.1.30
CB unit records iPSC lines records B3.1.31, C3.1.17, D2.1.11
CB unit disposition iPSC lines disposition B3.1.32, C3.1.18, D2.1.12
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2. Operational Standards and Bank Organization
From contacting donors to releasing a clinical-grade iPSC to an external partner for clinical use, a
long list of steps have to be followed and each step involves a considerable number of documents to be
created in the form of manuals, SOPs, records, lists and others that will assure the good management,
functionality, traceability and accounting of the bank. Figure 2 shows an example of a work flow with
associated documents for each step.J. Clin. Med. 2019, 8, 476 12 of 16 
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2.1. Bank Constitution and Juridical Status
2.1.1. A New Cell Bank: iPSC Bank Is a New Legal and Administrative Entity
An HLA-homozygous iPSC bank will have a well-defined objective that is different from the
CBB the original cells come from. Therefore, the iPSC bank should be created as a new legal and
administrative entity. However, the specific formula for creating the new entity and the determination
of the property of the cell lines will come down to each country and the national specific legal regulation
for pluripotent cells. Private CBBs surpass public CBBs in number and total number of units, and their
participation in constructing an iPSC cell bank would be of great interest; however, private CBBs have
been created and marketed for private use rather than donation to the common good [12,21]. An HLA
haplotype iPSC bank is conceived for an allogeneic use and the general opinion is that donors are not
to be compensated or personally benefit from the donation [22]. Some of the existing policies and SOPs
from the CBBs could be a guide for the iPSC bank; however, since the iPSC lines could have multiple
applications such as research, clinical trials or starting material for a cell therapy, new SOPs will have
to be created to deal with the lines requests, which will have to be considered one by one and will have
to include the approval of an ethics committee.
2.1.2. Repurposing the Samples: To Be Carefully Registered and Documented
Using the identified homozygous HLA from the CBBs to create the iPSC lines means that the cells
will not be used anymore for haematopoietic progenitor transplant as they were originally intended
when donated. In any case, a unit from the cord blood bank would only be transferred to the iPSC bank
if there is at least one other unit with the same haplotype, to ensure that future HSC recipients’ needs
can be met. Some authors argue that making iPSCs from banked CB could be done without ultimately
compromising their original use [14] since only a fraction of the cells are sufficient for efficient iPSC
reprogramming. However, in practice, the numbers of hematopoietic progenitors are already not
sufficient normally for one adult patient and taking away a fraction of the cells for reprogramming and
another fraction to keep as quality control for the generated iPSCs will hardly leave enough cells in the
sample for a successful transplant. Moreover, significant administrative and regulatory complications
would be generated in the process. When using banked CB units (or other banked biospecimens) as
starting material for making the iPSCs, the transfer of the CB units from the CB bank to the iPSC bank,
besides being explicitly included in the donor informed consent, should be done with the permission
of the legal health authorities that supervise the donors’ registry. The iPSC bank will create a new
product status for the transferred CB unit.
In conclusion, the process of taking a sample from a CBB to be transformed and stored in an iPSC
bank should be carefully registered and documented. New SOP and Registry documents should be
put in place to sign a sample out of one bank and into another cell bank.
3. Donor Management and Samples Collection
3.1. Information Brochure for the Donor and Informed Consent: Significant Differences in the Nature of
the Donation
The umbilical CB information for the donor and informed consent (IC) documents could be a
basis for defining an iPSC bank IC form. There are significant differences in the nature of the cell
donation compared to CB, mostly concerned with the long-term implications of iPSC lines such as:
(i) wider possibilities for research and medicine, including multiple therapies and recipients, and
(ii) still undefined purposes and commercial applications. Therefore, it is necessary to produce a new
document in which the potential donor is informed of the characteristics of the new donation:
# Uses for research and for transplantation into patients
# Possibility of a large number of different applications (more than one indication)
# Possibility of a large number of recipients
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# Commercial applications
# Whole-genome sequencing (WGS) for quality control purposes
# The possibilities of complete anonymization and of consent retrieval
Technically, the iPSC IC form is actually permission for transferring the already donated samples
to be used for a different application from the original purpose. A CB donation IC form that includes
the expressed acceptance of the donor to be recontacted paves the way for institutional permission to
call back the donors and engage them in the new project. In this sense, it is advisable to include the
possibility of recontact in the iPSC informed consent again, since new unforeseen possibilities might
come up in the future that require recontacting the donor.
Normally, CB donors are given the possibility of withdrawing consent up to the point of
transplantation. For iPSCs, on the contrary, many authors propose the possibility of withdrawal
up to the point of creation of the iPSC line given the considerable investment in money and effort
that is placed in creating one single line of clinical-grade iPSCs. In the same way, the possibility
of delinking all donor medical information to the coded sample is more of a delicate issue when
dealing with iPSCs compared to CB, since total anonymization would jeopardize many of the intended
applications [23], especially for clinical trials and transplantation therapies, as it prevents retroactive
validation. Complete anonymization does not completely guarantee anonymity and invalidates
the sample for diagnostic purposes and, for quality reasons or for carrying on longitudinal and
epidemiological studies, researchers might need to access the identity of the samples and link them to
medical journals and register data [24].
3.1.1. SOP for Recontacting and Obtaining the IC: Signing Procedures Are Valid and Legally Binding
The SOP should be defined for the sequence of events that takes place since recontacting the
identified homozygous donor until signature of the IC. All the ethical and legal aspects should be
considered so the donor feels well informed and not coerced, and so the IC form and signing procedure
are valid and legally binding. Creating a detailed SOP is particularly important for the cases in
which samples might be recruited from more than one CBB to create a single iPSC bank. The SOP for
recontacting and IC signature should include the information brochure for the donor, the IC form, the
documents for registering the follow-up of the process and a detailed description of the sequence of
events and the persons responsible for each step. Once the potential homozygous donors are identified,
they will be contacted and invited for a personal interview with a trained researcher or medical staff
involved in the project to get a full explanation of the nature of the project and the implications of the
sample cession. This interview should include an informative document and the donor should be
given the possibility to ask the interviewer any question she might have about the project. Also, the
donor should be offered the possibility of taking time to think about it and to consult with other people,
who might even include the baby whose cord blood was stored, and whose genetic information is
encoded in the cord blood cells. Therefore, the possibility of a second appointment should be offered
to give enough time to the donor to consider the consent. Some donors could be hard to locate as they
might have changed their contact details since the time of donation. However, the number of donors to
be recontacted is relatively small, especially when covering the most frequent haplotypes, and possible
back-up donors can be considered.
3.1.2. Friendly Information for Donor Autonomy During IC: Best Care and Information Is Essential
The background information for the donor that accompanies the IC form should be carefully
selected and laid out, not only due to the complexity of the scientific and technical aspects of the
intended use of the donated cells, but also to cover the specific social sensibilities for each country.
How a donor regards her identity and individuality, duty to the common good or altruistic willingness
to donate cells can vary considerably in each society. Even the trust of the donor in the scientific and
medical community can vary from place to place. Special emphasis should be placed on addressing all
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the key issues the donor should be aware of, using a register that is easily understandable for anyone
who is not an expert in the field and without creating unnecessary alarm or suspicions. Making sure
that the donor gets the best care and information is particularly important to respond to the donor
spirit of altruism and generosity and to be in line with the values of transparency, excellence and
service to society, as stated by Banc de Sang i Teixits and shared by all public blood and tissue banks.
3.1.3. Harmonizing IC Internationally: Consensus Point that Should Be Present in All IC for
Making iPSCs
Importantly, besides including all the local references to national legislation and cultural and
religious particularities, it is of crucial importance that the IC for making iPSC banks be harmonized
internationally. Some authors have published insightful considerations about consensus point that
should be present in all ICs for making iPSCs [25], some even with the specific perspective of the
case of using previously collected research biospecimens [25,26]. The European Bank for Induced
Pluripotent Stem Cells (EBISC) has issued a donor information leaflet template and the global Alliance
for iPSC Therapies (GAiT) will be delivering one soon too [27].
3.2. Health Questionnaires and Medical Records: Minimum Health Information Requirements Need to Be
Established to Set the Sample Inclusion Criteria for iPSCs
CBB medical information on donors can be used for iPSC banks. An extensive health questionnaire
is performed with CB donors during labour and shortly after delivery asking about mother and baby
general health, hereditary diseases in the family, blood transmittable diseases and transmittable
infections or risky behaviour. Some banks also use a postdelivery questionnaire at the time a recipient
for haematopoietic stem cell transplantation is identified. In this case, new information about the
mother’s health should be acquired at the point of donor selection. In cases where the questionnaire
was done a long time before the use of cells for reprogramming, updated information on the mother’s
and, particularly, on the child’s health should be collected, in particular information referring to the
appearance of serious diseases or genetic origin conditions. Similar SOPs, forms and data storage and
protection that were used for the CBB can be used for the iPSC bank. In some cases in which the child
might be of age at the time of recontacting, he or she might have some reticence on his/her mother
providing information on his/her health. In this case, minimum health information requirements
should be established to set the sample inclusion criteria to be part of the iPSC bank. In order to preserve
maximum confidentiality, personal information that can directly identify the donor should be kept in the
institution in which the original donation was done. The iPSC bank should be transferred the codified
medical records and other relevant information with the maximum protocols of data confidentiality.
3.3. Specimen Collection and Donor Eligibility: Step-by-Step Consideration
Collection of CB at delivery and the subsequent specimen acceptance are well documented
processes in a CBB, with specific policies, SOPs and instructions that have to take into account the
collection process and the mother and infant health. This process involves a large number of health
professionals such as nurses, obstetricians and laboratory qualified personnel. In the case of an iPSC
bank, the specimen collection step would be the one requesting specific HLA-homozygous samples
from the CBB collection, simplifying the number of SOPs, registries and training material involved in
this step.
Regarding donor eligibility, several articles with step-by-step consideration for making
clinical-grade iPSCs describe the criteria for CB eligibility emphasizing the importance of reviewing
the medical records, physical exams and clinical laboratory testing for relevant communicable disease
agents or diseases [19,28]. In the cases where the samples came from a CBB, these considerations were
already taken into account when the CB units were accepted in the CBB. The test for viral blood-borne
pathogens (HIV, HBV, HCV, CMV and others emerging or endemic to the donor’s origin) on maternal
samples as donor surrogate are mandatory in Europe according to the Cell and Tissue Directive
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(Directive 2004/23/CE). If data and techniques used are up-to-date, this information could be used for
the iPSC bank.
3.4. Genotyping for HLA: Harmonize the Information from CB to iPSC
When umbilical CB units are included in the CBB registries, HLA typing is required. CB banks
have been run for long periods of time and the degree of resolution can vary and often low-resolution
techniques like serological, and more recently, DNA-based methods such as sequence-specific
oligonucleotide probes (SSOP) or sequence-specific primer (SSP) PCR can coincide. When the specimen
was identified as a suitable donor, a higher resolution method was used such as sequence-based
typing (SBT) using Sanger sequencing. However, the introduction of Next-Generation Sequencing
(NGS) in the determination of HLA haplotypes has united high throughput with high resolution.
New developments allow for HLA determination at very high resolution of big numbers of samples
simultaneously, for a low price [29,30]. Therefore, given the advantages and universalisation of NGS
for HLA typing, this is probably the method of choice for HLA confirmation of the homozygous before
being selected for reprogramming and inclusion in the iPSC bank. Therefore, SOPs describing the
HLA retyping of the HLA-homozygous CB units should be put in place to harmonize the information
in all the samples.
For the HLA-homozygous selection, a projection of coverage of the target population needs to
be done, and to do this, access to a large database of HLA samples is necessary. It is important to
keep a registry of all the associated documents from ethics committees, IC, data privacy and so forth,
associated with the use of the database, and compliance should be reflected in the SOPs for iPSC use.
3.5. Notification of Relevant Clinical Data and Counselling: New Information Regarding Potential Health
Threats with iPSC
CBBs have in place SOPs to notify positive or indeterminate results of (i) infectious diseases,
(ii) genetic testing and (iii) the event of unexpected adverse effects in a transplant recipient. The quality
controls performed with iPSC-generated data may reveal new information regarding potential health
threats for the donor, so specific policies and SOPs should be created for this purpose. Since the
samples will be coded in the iPSC bank and only the original CBB that provided the original cells have
the donor personal information, the iPSC bank must actually notify the CBB and there, the medical
coordinating staff should decide about donor notification and counselling.
4. iPSC Production
4.1. Cell Reprogramming to iPSC: With GMP-Compliant Processes in Clinical-Grade Facilities
Unlike CB banking that involves nonsubstantially manipulated stored specimens, the
manufacturing of iPSC lines is a more complex process requiring not only well-defined cell lines but
also a very extensive cellular characterization, viral and microbial status determination and product
potency assay to show identity, safety and pluripotency capacity after manipulation, respectively.
Though there are no international established standards for clinical-grade iPSCs at the time of
writing this review, iPSC lines—or more precisely, iPSC-derived cell products—fall under the definition
of Advanced Therapy Medicinal Products [31,32] and as such, these should be produced following
Good Manufacturing Practices (GMPs). Several publications have set up the discussion about these
standards [19,23,33] and previous literature on hESCs can be of guidance for the iPSC field [34,35].
From our point of view, there would be at least two possible approaches to create a clinical-grade
iPSC bank in accordance with current regulations in EU:
1. Performing the whole process, reprogramming of iPSC lines, downstream manipulations and
cryopreservation, under cGMP conditions.
2. “Cleansing” already reprogrammed iPSCs into cGMPs.
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The first approach represents what is the classic pharmaceutical implementation of manufacturing
processes of medicinal products but involves the inversion of a high quantity of resources that few
institutions consider affording at least until some therapeutic therapy based on these cells have clearly
shown to work.
The second one represents a strategy similar to some hESC lines that have been previously used
in a clinical setting and for which starting material was isolated in research-grade conditions and later
transitioned into GMPs [36].
In this regard, existing European guidelines on GMPs specific to ATMPs on article 7.35 [37] refer
to this issue and seem to consider that, in exceptional cases and after evaluation and explicit approval
of competent authorities, the design of a battery of quality control tests and specifications able to assure
the quality of this kind of starting material could give rise to a regulatory acceptance to be further used
to manufacture an ATMP.
In view of the above, the “cleanse” of iPSCs manipulated out of GMP compliance approach should
be suitable for well-characterized cell lines made during research and development investigations,
implying complex and highly specialized manipulations not within the reach of much of the
research teams and thus representing a material nearly impossible to replace with other ones that
are GMP-compliant.
In the case that iPSCs are partially produced in a non-GMP-compliant environment, the use of
xeno-free and feeder-free processes and an exhaustive traceability of all the steps and raw material will
be fundamental for later regulatory approval as a medicine as well as following specific requirements
for raw materials of biological origin for the production of cell-based therapy medicinal products. It is
essential to create a “Cell Line History” file for each iPSC in the bank, to keep a history of the cells. The
clinical utility of an iPSC line could be compromised if some information or documents are not present
in the file. The International Stem Cell Banking Initiative (ISCBI) published a list of typical information
that might be required in a cell line history [30]. In any case, the final expansion and stock production,
quality control and storage should be made with GMP-compliant processes in clinical-grade facilities.
All the steps of the reprogramming and expansion processes should be carefully documented
and traceability assured. SOPs, procedure descriptions, registries and listings should be written for
every step of the process, batch records, facilities and instrumentation maintenance and supply chain
guarantees. It is also necessary to define specifications (quality and security requirements) that should
be met by any ATMP manufacturer eventually interested in using the iPSC as starting material. Also,
back-up suppliers for every reagent and material should be provided. If a part of the process takes
place in a non-GMP facility, still an effort should be placed in keeping records and documentation
collection as extensive as possible and the risks and implications of the specifications of the future
ATMP should be evaluated and registered.
4.2. Cell Characterization Pipeline
Though acquisition of self-renewal and pluripotency capacity assays are quite well generalized in
the scientific community, there is still no international guideline that will serve as reference for iPSC
banks and for regulators to accept them as starting material for therapies, although considerable effort
is being put into it internationally by the scientific community, health institutions and commercial
companies [38]. The International Stem Cell Banking Initiative and GAIT have issued consensus
guidelines that are useful reference for characterization and quality control and safety [19], including
reference to applicable pharmacopeial methods when available [33]. There is consensus in the
assessment of Alkaline Phosphatase activity and of the expression of classical pluripotency markers
by flow cytometry, such as OCT3/4, NANOG, SSEA4, TRA-1-60, TRA-1-81 [33,37], though protein
expression by immunofluorescence has widely been used in the field. For differentiation capacity,
formation of tissue of the three germ layers—endoderm, mesoderm and ectoderm—is an obvious
must, but whether in vivo teratoma formation is required or in vitro embryoid bodies formation
or directed differentiation is sufficient still remains to be settled. Pluripotency markers and three
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germ layers gene expression at the molecular level are still not viewed as mandatory, although the
now-available standardized commercial kits for this purpose (hPSC ScorecardTM or PluritestTM)
would make harmonization and evaluation much easier. SOPs for genomic instability have not been
considered and are discussed in more detail below.
4.3. Quality Control and Safety: Long-Term Clinical Success of iPSCs Needs Stringent Guidelines of Genetic Stability
Some mandatory safety tests are common to the products in a CBB, such as microbiological
sterility (virus, bacteria and mycoplasma), endotoxin or pyrogenicity, and there are established tests
institutionally recognized. In the case that the iPSCs have been cultivated with antibiotics, additional
validations should be put in place for the sterility tests (test suitability).
Unlike CB cells, which are minimally manipulated before storing, the process of reprogramming
into iPSCs involves overexpression of the reprogramming factors, several weeks in cell culture and the
reprogramming process, which itself causes great stress to the cells.
Regarding the reprogramming method, different reprogramming methods have been used to
create iPSCs such as retroviral vectors, lentiviral vectors, plasmids, mRNA or recombinant proteins [39];
however, nonintegrative methods—to avoid the risk of insertional mutagenesis—are the choice when
it comes to making clinical-grade iPSCs, in particular, mRNA, Sendai virus or episomal vectors [40]. In
any case, the use of exogenous recombinant nucleic acids makes these three approaches fall into gene
therapy category for the regulatory agencies [41].
Altogether it is mandatory to include a series of safety tests that include karyotyping for gross
chromosomal abnormalities, Short Tandem Repeats (STRs) for identity and RT-PCR for residual vector
clearance. Vector clearance, especially of viral origin vectors, is an important aspect to settle to later
go through regulatory approval and at the moment there are no accredited laboratories offering this
assay. Therefore, special care should be taken by each lab in developing this assay, taking into account
a standard curve, an internal reference and two different regions [33].
Genomic stability is a particularly concerning issue to the iPSC field. If the field of human iPSC is
to have long-term clinical success in transplantation in humans, then stringent guidelines to the level of
genetic stability analysis including WGS need to be considered. Many reports have raised the concerns
over the genomic stability of iPSCs, especially when the cells are intended for clinical use, and in many
cases for life-long engraftment into the patient [42]. The first clinical trial using iPSC-derived cells, the
RIKEN trial in Japan [43], stopped the assay in the second patient since three single-nucleotide variations
(SNVs) and three copy-number variants (CNVs) were found in the iPSC line that were not present in the
patient’s original cells before reprogramming [44]. Therefore, single-nucleotide polymorphisms (SNPs)
and comparative genomic hybridization (CGH) arrays have been proposed as regular tests before releasing
iPSC lines into clinical use to detect changes in the genome at higher resolutions, like CNV. Moreover, NGS
has allowed WGS at a more affordable price and the detection of genomic alterations at the nucleotide
level. However, the threshold of genomic alterations for the acceptance of the iPSC in the clinical-grade
bank is still to be settled. Although a huge amount of information can be deduced with arrays and NGS,
the general acceptance is that high-resolution genetic analysis is necessary before clinical approval of iPSC
lines [45]. Further consideration needs to be given to the interpretation of the fitness of an iPSC line and its
tumorigenic potential extracted from WGS or CNV data obtained with these assays and where to set the
acceptance threshold. Consequently, it is a matter of debate if high-resolution assays are to be included in
the quality and safety control SOP for an iPSC bank.
5. Data Management and Sample Release
5.1. Data Collection and Confidentiality: How and When to Retrace to the Original Donor Information for
iPSC Bank
When the specimens to be reprogrammed are directly obtained for creating an iPSC bank, the
SOP should describe the personal and medical data collection and registration in a way similar to how
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they are collected for a CBB, including donor contact data, medical records and a full description of
material procurement. When the cells come from a previous bank, as would be the case for a CBB to
become part of the iPSC bank, the personal information identifying the particular donor should stay
with the original bank and only the coded medical and basic information (date of birth, country of
origin) stored in the iPSC bank. However, careful planning on how and when to retrace to the original
donor should be reflected in the SOP with data protection.
Specific SOPs will have to be generated to account for the confidentiality of the genetic data that
is generated with STR fingerprinting and WGS and that could eventually lead to identification of the
original donor and be potentially misused. The new European General Data Protection Regulations,
effective since 2018, have implications to anyone who generates banks or distributes human-derived
iPSCs and associated data and it is strengthening the focus on accountability, transparency and data
minimization [46]. Hopefully, best practice standards for genetic data management for iPSC banks will
be soon standardized and available [47].
5.2. Sample Release: Only Released as Stated in the Informed Consent
Besides the technical SOP describing the freezing, storage and transportation processes for the
bank specimens, additional aspects have to be considered in the sample release SOP. Unlike CBBs,
which aim to be a source of hematopoietic progenitors for a limited number of blood disorders, with a
few newer applications (plasma or endothelial progenitors), the intended uses of the iPSCB samples
by researchers and clinicians are numerous and many yet unknown. It is important to set up all the
procedures and documentation that will assure that the samples are only released as stated in the
informed consent originally signed by the donors, which might include some limitations on the use of
the cells or a revision of the projects by an Ethics Committee.
6. International Harmonization of HLA-Homozygous iPSC Procurement and Production:
Facilitates Clinical Use of iPSC-Derived Cell Therapy Products
HLA-homozygous iPSC banks would be particularly useful if international cooperation is in place,
since the effort to create enough lines to cover all the national population is mostly unattainable by a
single blood cell bank for most countries and sample sharing can substantially increase the coverage
for a country. Also, for clinical trials and commercial applications, harmonizing and standardizing the
quality and characteristics of the iPSC lines in the different banks are particularly relevant. Therefore,
special emphasis is focused on standardization of iPSC production, characterization and quality control
of the iPSC produced worldwide. Several initiatives, for example, Global Alliance for iPSC Therapies,
are working in this direction. Table 2 shows the most relevant legislation concerning the production
of an iPSC bank for clinical use. International harmonization of national or regional legislations and
guidelines is greatly expected to facilitate the clinical use of iPSC-derived cell therapy products.
Table 2. Current legislation concerning the production of cell-based therapies.
EU USA Japan
Tissue procurement EU Tissues and Cells Directive 2004/23/EC.EU Blood Directive 2002/98/EC
FDA 21 CFR 1271 Human Cells, Tissues and
Cellular and Tissue-Based Products
The Act on Safety of
Regenerative Medicine.
MHLW (25/11/2014)
GMP Directive 2003/94/EC GMP for medicinaland investigational products for human use
FDA 21 CFR 201 Subchapters D (Drugs for
Human Use) and F (Biologicals)
Clinical use EU Tissues and Cells Directive 2004/23/EC FDA 21 CFR 50, 56, 210, 312, 314, 320, 812, 814
Quality and safety EU Tissues and Cells Directive 2004/23/EC FDA 21 CFR 600, 601, 610
Guidelines on Ensuring the
Quality and Safety of
Products Derived from
Processed HUMAN Stem
Cells MHLW No.
0907-2,3,4,5,6
7. Summary: Impact on Future Developments
Repurposing donated cord blood units and developing high-quality and diversified iPSC lines
are feasible. Adaption of CB SOPs to create international SOPs for iPSC clinical use has been proposed
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in this review. Qualified CB banks and CB units are essential for starting material for developing
tissue-specific stem cell therapies in an allogeneic setting using HLA matching. The large availability
of validated CB units (it is estimated that more than 700,000 public CB units are available worldwide)
makes it possible to identify the appropriate haplotypes that cover a defined population. Aggregation
of all ethnic groups will ensure equal access to the iPSC therapy for all patients in need.
The stringent quality assurance programs in CB banking will help the development of high-quality
and diverse iPSC cell lines. Use of standardized protocols will allow the desired strategy to generate
a worldwide iPSC banking registry. The addition of cell lines with particular haplotypes will help
academic and commercial developers in the goal of generating tissue-specific stem cells that will
contribute to the translation of regenerative medicine to treat human disease.
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